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 David L. Rowland1*, Ion G. Motofei2, Ioana Păunică2, Petrișor Banu2, Mihaela F. Nistor2, 
Stana Păunică3, Vlad D. Constantin2      
 1Valparaiso University, Department of Psychology, Valparaiso, Indiana, USA 
2Carol Davila University of Medicine and Pharmacy, Faculty of General Medicine, Bucharest, Romania    
3Carol Davila University of Medicine and Pharmacy, Dan Theodorescu Hospital, Bucharest, Romania    
  
Abstract Finasteride is currently approved and largely used as a therapeutic option for androgenetic 
alopecia. Apparently a safe drug and effective at the onset of its application, several concerns 
have since appeared over the years regarding the frequency and magnitude of finasteride adverse 
effects, which in some cases appear irreversible even after drug termination. 
This paper discusses the use of finasteride for androgenic alopecia from two distinct 
perspectives. On the one hand, androgenic alopecia is a condition that especially affects a person’s 
self-image and esteem, aspects that are subjectively-constructed and thus relative and changeable. 
On the other hand, this condition involves a multifactorial etiology, with androgens being only 
partly responsible. Because androgens have important and unique physiological roles within the 
body, any procedure that results in androgenic suppression should be advised with caution. 
Furthermore, adverse effects induced by finasteride are neither fully documented nor easily 
treated. Finally, as alternative therapeutic approaches (such as topical finasteride) become 
available, the oral administration of finasteride for androgenic alopecia should, in our opinion, be 
reevaluated.  Due to such concerns, a detailed and informed discussion should take place with 
patients considering therapy with finasteride for androgenic alopecia.   
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Highlights ✓ Finasteride administration places the subjects with androgenic alopecia into an abnormal 
state, characterized by a low level of DHT  
✓ Finasteride adverse effects persist in some men indefinitely after treatment cessation, the 
corresponding medical support being non-specific, namely symptomatic    
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Introduction 
Androgenetic alopecia (AGA) is not considered an 
effective disease, as it has minimal or no impact on body 
physiology. However, it is currently accepted as a 
relatively benign affection that not only has a 
psychological impact but also has variable psycho-
social implications. Some individuals adapt well to 
AGA, while others seem to be severely disturbed, the 
condition being associated with decreased self-esteem, 
stress, and even depression (1). Depending on 
geographic region and culture, bald people are 
sometimes perceived by others as less attractive and 
older (2). Studies performed on patients with hair loss 
have shown that younger individuals and those with 
longer duration of AGA are generally more severely 
affected regarding self-esteem and social perception (3).    
Various therapeutic approaches for AGA have been 
proposed and tested in clinical practice, with topical 
minoxidil and oral finasteride both currently approved 
by the US Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) as treatment 
options. Before beginning therapy, patients must be 
advised that ongoing administration is required in order 
to achieve and maintain therapeutic benefits on hair loss 
(4).  
Other therapeutic strategies have been also tested, 
some positive results being observed with Alfatradiol 
(17-α-estradiol), latanoprost, bimatoprost, 
ketoconazole, and various topical reagents (5). 
Furthermore, recent studies with platelet-rich plasma 
(alone or in combination with minoxidil) seem 
promising in the management of AGA (6). A surgical 
approach toward AGA includes autologous hair 
transplantation using hair follicles especially from the 
occipital area. For both men and women, predicted 
results are generally considered acceptable; however 
this procedure can be performed only by an experienced 
surgical team. Moreover, implantation of prosthetic hair 
is associated with some (non-negligible) adverse effects 
(7). For women with AGA, the use of several drugs such 
as cyproterone acetate, spironolactone, and flutamide 
have been investigated. Such compounds have shown 
only modest results in ameliorating AGA, a better effect 
being obtained in women with hyperandrogenism (8).   
All therapeutic solutions presented above have 
variable adverse effects and relatively limited results 
(which can be maintained only through ongoing 
administration of the drug), so that the choice of the 
most adequate therapy is not straightforward. This paper 
continues a series of articles focused on finasteride 
administration for androgenic alopecia that better 
evaluate the opportunity of long term use of an oral 
chemical compound for a biological condition having 
non-life-threatening implications.  
 
Discussion 
Inhibitors of the 5α-reductase enzyme such as 
finasteride and dutasteride are currently approved and 
administered for benign prostatic hyperplasia, while for 
androgenic alopecia these same compounds are the 
subject of controversy in the literature. Several studies 
suggest that finasteride should be used with caution for 
AGA due to the considerable adverse effects induced in 
some men (9). These adverse effects are the 
consequence of the action of finasteride in decreasing 
the conversion of testosterone into the more potent 
metabolite, dihydrotestosterone (DHT), a natural 
compound that plays a critical role in the process of 
growth and maintenance of several functions of tissues 
and organs (thereby modulating important biochemical 
signaling pathways of human physiology). In support of 
this idea, testosterone deficiency, for example, is a 
recognized medical condition with a specific 
symptomatology. Administration of exogenous 
testosterone in hypogonadal men leads to correction of 
the plasmatic level of testosterone, which often is 
followed by amelioration and subsequent disappearance 
of the symptomatology (10).    
Inhibitors of 5α -reductase enzyme therefore have 
the potential to induce a veritable hypogonadal status, 
yet in turn, the same 5α -reductase inhibitors have the 
capacity to ameliorate androgenic alopecia. 
Accordingly, administration of finasteride and 
dutasteride for androgenic alopecia might be viewed in 
two very different ways. Taking into account only its 
therapeutic efficiency for AGA, several authors have 
demonstrated that dutasteride (a stronger inhibitor/ more 
potent antiandrogen than finasteride) produces superior 
results in ameliorating androgenic alopecia than 
finasteride, such that it should be preferred in clinical 
practice for AGA (11).  
In contrast, from the perspective of drug safety and 
adverse effects, other authors have resisted the use of 
dutasteride and, further, suggest that oral finasteride 
should be replaced with topical administration. Studies 
have shown that both scalp and plasma DHT levels 
significantly decrease after topical application of 
finasteride, while no changes of testosterone levels were 
registered in plasma. In all studies investigating topical 
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finasteride, significant decreases in the rate of hair loss 
and increases in total and terminal hair counts (4) were 
noted. 
1. Pharmacology of finasteride 
Generally, inhibition of the 5α-reductase enzyme by 
this drug disrupts the conversion of testosterone to DHT, 
resulting in a decrease in serum DHT levels by about 65-
70%. Thus, finasteride does not completely suppress 
DHT production because it lacks significant inhibitory 
effects on the 5α-reductase type I isoenzyme, the main 
inhibitory effect being on the type II and III isoenzymes. 
In fact, the action of the 5α-reductase enzyme is more 
complex, intervening in the metabolism of multiple 
neurosteroids within the brain (e.g., testosterone, 
progesterone, deoxycorticosterone, etc.), 
neuromodulators that further interfere with cerebral 
activation of GABAA receptors (12). By inhibiting the 
5α-reductase enzyme, finasteride leads to several 
hormonal abnormalities and GABA disruption, with 
important implications on various neurophysiological 
processes of the brain. Such interference is encountered 
not only during finasteride administration but also after 
treatment cessation, which is clinically expressed as the 
post-finasteride syndrome. Men with post-finasteride 
syndrome present—at considerable periods of time after 
the therapy termination ranging from months to years—
disturbed levels of specific neurosteroids in 
cerebrospinal fluid and plasma, including: increased 
testosterone, pregnenolone, 5a-androstane-3a, 17b-diol, 
and decreased progesterone, dihydroprogesterone, 
dihydrotestosterone, and allopregnanolone (13).  
After finasteride administration, circulating levels 
of testosterone and estradiol slightly increase (by up to 
15%), remaining however within the physiologic range, 
though qualified by the fact that testosterone is much 
less active than DHT, which decreases significantly. 
Similar variation has been observed for luteinizing 
hormone and follicle stimulating hormone, which 
increase by about 10% during finasteride administration 
though without exceeding physiological levels.  
Finally, studies show that finasteride action is more 
complex than initially assumed, inhibiting not only 5α-
reductase but also competitively inhibiting the 5β-
reductase (AKR1D1) and other possible enzymes (14).   
Oral administration of finasteride is not affected by 
food, having a good absorption and a bioavailability 
around 65%. The maximum plasmatic concentration is 
reached about 1-2 hours after administration, successive 
doses leading to a slow accumulation of the drug, with 
plasma protein binding of finasteride being about 90%. 
finasteride crosses the blood-brain barrier, this capacity 
of the drug being able to explain many finasteride side 
effects, like mental and sexual impairment. 
Finasteride (administered orally) is extensively 
metabolized by cytochrome P450 in the liver, the 
resulting metabolites having (comparable to finasteride) 
no more than 20% inhibitory activity. Oral 
administration of finasteride produces a significant 
decrease of plasmatic DHT concentrations during the 
first 6-8 hours, and this effect persists for about 24 hours 
for a single dose, and longer for repeated 
administrations. Daily administration of finasteride 
suppresses the serum DHT level by about 65-70%, 
depending on the dose.  
Excretion is largely realized as metabolites through 
urine (about 39%) and feces (57-60%). The mean 
terminal half-life of finasteride is about 7 hours, shorter 
in younger men and longer in men over 70 years (15).     
 
2. Adverse effects of finasteride 
Finasteride side effects are the consequence of 
cerebral interferences of this drug with sexual 
neuromodulators and GABAA receptors, although a 
direct action of finasteride on cerebral receptors cannot 
be excluded. Such adverse effects described in the case 
of finasteride can be absent or negligible (anhedonia, 
lack of mental concentration, insomnia, chronic fatigue, 
elevated body mass index), or in contrast, quite severe 
(depression, suicidal ideations, impotence, erectile 
dysfunction, decreased libido, ejaculation disorders) 
(16, 17).  
Due to interference with GABAA receptors, 
finasteride seems to change tolerance to ethanol in some 
individuals, with former users of finasteride reporting a 
variable decreasing tolerance to alcohol (18). Other 
studies have reported possible connections (if not causal 
relationships) between finasteride administration and 
the occurrence of different forms of neoplasia, such as 
high-grade prostate cancers or male breast cancer (19, 
20). If finasteride is administered to early pregnant 
women, contraception should be taken into account due 
to a potential embryoteratogenic effect, while in 
postmenopausal women finasteride seems to be 
effective only at high doses (21). 
Finally, hormonal disturbances and GABA 
interferences from finasteride are encountered not only 
during the drug administration but also after treatment 
cessation in some patients, with corresponding clinical 
manifestations in the form of the so-called post-
finasteride syndrome. The most frequent manifestations 
of post-finasteride syndrome are relatively similar with 
finasteride side effects occurring during drug 
David L. Rowland et al. 
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administration, being represented especially by 
mental/psychological impairments and sexual disorders.  
3. Inconsistent adverse effects of finasteride 
Recent studies suggest that the main (mental and 
sexual) side effects of finasteride would be encountered 
only in a subset of men, according to structural and 
informational dichotomies of the brain. These two 
neuro-physiological processes of the brain are 
presumably interrelated with hand preference and sexual 
orientation in both men and women (22-24).  
Informational dichotomy of the brain is closely 
related to two distinct and opposite cerebral networks 
(task positive network and default mode network), 
sexual hormones acting on the concrete mind while 
sexual pheromones preferentially activating the abstract 
mind (25). Structural dichotomy of the brain results 
from the lateralization process of the brain, with 
androgens and female pheromones activating the left 
hemibrain, and estrogens and male pheromones 
activating the right hemibrain (26, 27).  
According to this line of thinking, finasteride 
adverse effects would be encountered most strongly in 
right-handed persons who present a concrete-thalamic 
psycho-physiologic profile. In contrast, left-handed men 
with a concrete-thalamic profile would be less likely to 
develop side effects.  
Thus, hand preference and psychological profile/ 
sexual orientation could be used as possible predictive 
factors for finasteride side effects, being therefore able 
to delineate, prior to treatment, patients having a lower 
risk for developing sexual side effects to the drug. For 
those men with androgenic alopecia having a lower 
predicted risk for adverse effects, the use of finasteride 
would be presumed safe (7).  
4. The risk-benefit ratio of finasteride administration 
in androgenic alopecia  
To appreciate the risk-benefit ratio of finasteride 
administration on patients with androgenic alopecia, it 
is first necessary to establish the major elements that 
influence the evaluation. 
• First, male androgenic alopecia is a benign condition 
with a multifactorial etiology, being only in part 
induced/ supported by DHT. Other non-hormonal co-
factors are also involved, as those with androgenic 
alopecia actually have a normal (non-elevated) level of 
DHT. Thus, finasteride administration places subjects 
with androgenic alopecia into an abnormal state, 
characterized by a low level of DHT. 
• DHT, the most active androgenic compound, has its 
own (neuro-endocrine, metabolic, etc.) physiological 
roles within the body, and its suppression should be 
carefully advised. As an example, recent studies show 
that 5α-reductase-2 deficiency leads to reduced 
dominance-related and impulse-control behaviors (28). 
In addition, studies using functional magnetic resonance 
imaging show that men with post-finasteride syndrome 
(consisting of sexual dysfunctions and major 
depression) revealed abnormal function in brain 
connectivity (29). 
• More importantly, adverse effects induced by 
finasteride are incompletely documented. In support of 
this point, mental and sexual functions, generally 
affected in tandem by finasteride, lead to specific 
disorders such as sexual dysfunctions and depression, 
which may potentiate one other and which do not 
respond well to established/ etiological treatments. 
Furthermore, the post-finasteride syndrome itself has yet 
to be fully elaborated (17). 
• Adverse effects from finasteride have generally been 
investigated only over relatively short periods of time. 
Important additional data are needed to understand 
potential metabolic implications that might develop 5-
10 years after finasteride cessation.  
• Study design and procedures should also be 
revisited. For example, the frequency and magnitude of 
finasteride adverse effects strongly depend on the study 
protocol, being higher when patients are advised (before 
the therapy) of possible adverse effects, and lower (or 
ignored) when the patients are not advised (30).  
 
• Alternative therapeutic approaches are becoming 
available, such as topical application of finasteride 
which bypasses the liver (toxicity) and which results in 
higher concentrations in the scalp skin at low doses than 
oral administration.  
• Finally, androgenic alopecia is a condition that can 
affect one’s self-image and esteem, aspects that are 
subjective/ relative and thus changeable over time. 
Contrary to this perspective, a possible post-finasteride 
syndrome could persist indefinitely in time, and subjects 
must be informed before therapy about these aspects. 
 
Conclusions 
 Although not an exhaustive presentation, here we 
attempted to highlight the importance of patient 
informing and consent before commencing therapy with 
finasteride for androgenic alopecia. Generally, men who 
seek medical support for androgenic alopecia seem to be 
more emotionally distressed than others, while adverse 
effects occurring in those with post-finasteride 
syndrome can persist indefinitely in time.  
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